◢ SPACE MEDICINE FOUNDATION
⌕ Search
Space weather
Geomagnetic storm level: Loading…
Solar radiation level: Loading…
Updated --:-- -- ET · educational only
EDUCATIONAL RESOURCE · Educational use only — not medical advice and not operational guidance. Disclaimer

Home › Learn › Case files › Spaceflight participant with hypertension

AI-assisted content for educational use only; not medical advice and not operational guidance. Reviewed: clinical review Oct 14, 2026 (AI-assisted), by an AI medical research assistant, not a named human clinician. Items marked “pending verification” could not be confirmed against a primary source. Disclaimer

Fictional composite case

This case is invented for teaching. It combines typical features from the cited sources and describes no real astronaut, spaceflight participant or patient. No real patient data were used.

LRN-21 · Teaching case (fictional) · Learn

Case File: A Commercial Spaceflight Participant With Hypertension

Gravity FieldsCardiovascularBehavioral Health & SleepVestibular & SensorimotorSelection & CertificationPreflight & TrainingLEO short-durationSuborbitalClinicianOperator / Spaceflight participant

AI-assisted Last reviewed: 2026-10-14 · Reviewer: AI-assisted clinical review (AI medical research assistant; no named human clinician)

Bottom line
  • The operator decides fitness. U.S. rules require informed consent and training, not medical standards, for spaceflight participants [1]. ◆◆◆◆ High · E
  • FAA 2006 guidance suggests full history, exam and labs for orbital flights (tier 2) [2]. ◆◆◆◇ Moderate · E
  • Volunteers with well-controlled hypertension and other conditions tolerated simulated suborbital G-profiles in a centrifuge [3]. ◆◆◇◇ Low · A
  • Anxiety reactions were the hardest to predict [5]. ◆◆◇◇ Low · A
  • Beta-blockers were the drug class most strongly associated with orthostatic hypotension in randomized trials; diuretics add to spaceflight volume loss [8][7]. ◆◆◆◇ Moderate · E

Proposed certainty (◆ High → ◇ Very low) and evidence-type tags: F flight · A analog · M model/animal · C computational · E expert/operational/standards. AI-proposed, pending reviewer confirmation. How to read the grades.

Presentation

A 64-year-old retired engineer has booked a seat on a 3-day orbital flight with a commercial operator. He asks you, his primary care clinician, for “a letter clearing me for spaceflight.”

  • History: high blood pressure for 10 years, treated with two medicines; home readings average 128/78 mmHg. Mild knee arthritis. No chest pain, fainting or palpitations. Car sickness as a child. He says he “gets a bit tense in small elevators.”
  • Exam: blood pressure 132/80 mmHg seated, no drop on standing. Heart, lungs and neurological exam normal.
  • Tests: 12-lead electrocardiogram (ECG): normal sinus rhythm, no abnormalities.

He has not yet heard from the operator’s medical team.

Questions

  1. Who decides whether he is medically fit to fly, and what should your letter say?
  2. What level of screening does the FAA’s 2006 guidance suggest for an orbital flight?
  3. Is well-controlled hypertension likely to stop him from tolerating launch and landing G-forces?
  4. What else in his history deserves attention?

Think through your answers before opening the reveals below.

Reveal

Question 1: answer and discussion

Who decides whether he is medically fit to fly, and what should your letter say?

The operator decides, not you and not the government. U.S. rules under 14 CFR Part 460 do not set medical standards for spaceflight participants (SFPs). Instead, operators must give each participant written information about known and unknown hazards and train them for emergencies [1].

Your role is to optimize, document and communicate: control his blood pressure, summarize his history, medicines and test results, and send them to the operator’s flight surgeon. SMF’s spaceflight participant screening article suggests wording such as “no contraindication identified to the operator’s medical evaluation” rather than “cleared for spaceflight.”

Question 2: answer and discussion

What level of screening does the FAA’s 2006 guidance suggest for an orbital flight?

The Federal Aviation Administration (FAA) guidance (DOT/FAA/AM-06/1) is advisory. It describes two tiers [2]:

TierFlight profileSuggested screening
1Suborbital, up to +3 GzMedical questionnaire reviewed by a physician trained or experienced in aerospace medicine
2Orbital, or any flight above +3 GzFull questionnaire, physical exam and lab tests, valid 1 year, with a brief update 1–2 weeks before flight

His orbital flight falls in tier 2. “Gz” means head-to-foot acceleration (G-load).

Question 3: answer and discussion

Is well-controlled hypertension likely to stop him from tolerating launch and landing G-forces?

Probably not, based on centrifuge data, but the evidence is limited. In a centrifuge study, 86 volunteers aged 20–78 with high blood pressure, heart disease, diabetes, lung disease or back problems rode simulated suborbital profiles (up to +6 Gx and +4 Gz). Heart rate peaked at 192 beats per minute and systolic blood pressure at 217 mmHg. Grayout (69%), nausea (20%) and chest discomfort (6%) were common, yet no subject had a significant adverse physiological response [3]. The authors concluded that most people with well-controlled conditions can tolerate these forces [3]. Note the selection: volunteers with severe or uncontrolled medical disease were disqualified before testing [3].

These were short centrifuge runs, not real flights, and they modeled suborbital rather than orbital profiles. The FAA guidance advises care with rapid-onset profiles of +3 Gz or more sustained for 5 seconds or longer in people with compromised cardiovascular function [2]. Uncontrolled high blood pressure is different: it needs treatment and a flight-surgeon review.

Escalate before writing any letter if you find: uncontrolled blood pressure; left ventricular hypertrophy or strain on the ECG; angina or evidence of ischemia; unexplained fainting; or a drop in blood pressure on standing at baseline. The IAA study group lists uncontrolled hypertension and autonomic neuropathy with hypotension among conditions that acceleration can make worse [4].

Question 4: answer and discussion

What else in his history deserves attention?

  • Anxiety in confined spaces. In the centrifuge studies, three of the five volunteers who withdrew did so because of anxiety [3]. The screening authors wrote that better methods are needed to identify people prone to anxiety reactions [5]. Mention it to the operator’s flight surgeon.

  • Motion sickness. Childhood car sickness does not reliably predict space motion sickness (SMS); a previous episode of space motion sickness does. Most first-time flyers get it in the first 2–3 days [6].

  • Landing day and his blood pressure medicines. Even short orbital flights shift body fluids. Circulating blood volume falls by about 15% within about 2 days in weightlessness, which causes lightheadedness on standing after landing (orthostatic intolerance) [7]. Some drug classes make this worse:

    • Diuretics add to the volume loss. An International Academy of Astronautics (IAA) study group also lists diuretics among medicines that reduce heat tolerance [4].
    • Beta-blockers blunt the heart-rate rise that compensates on standing. In a meta-analysis of randomized trials they were the class most strongly associated with orthostatic hypotension (odds ratio 7.76 vs placebo) [8]. In an FAA-sponsored crossover trial, atenolol modestly impaired orthostatic tolerance under lower-body negative pressure [9].
    • Alpha-blockers carried a smaller increase in risk (up to about twofold) [8]. Medication review is the recommended first step for drug-related orthostatic hypotension [10].

    What to do: name each of his medicines and doses in your letter, and ask the operator’s flight surgeon whether any should be changed, held or re-timed around launch and landing. Do not stop a beta-blocker abruptly, and make any change well before flight so its effect can be checked. Always record lying and standing blood pressure and heart rate (orthostatic vitals).

  • Knees. Ask about mobility for emergency exit training, which Part 460 requires [1].

Teaching points

  • Commercial operators, not regulators or the patient’s own clinician, decide medical fitness for spaceflight participants [1].
  • FAA screening guidance from 2006 is advisory and splits screening into two tiers by flight profile [2].
  • Centrifuge data suggest most people with well-controlled chronic disease tolerate suborbital G-profiles. These are analog data from volunteers [3].
  • Anxiety was the hardest problem to predict in centrifuge trials [5].
  • Review blood pressure medicines before flight: diuretics and beta-blockers worsen landing-day orthostatic intolerance; changes belong to the flight surgeon and should be made well before flight [7][8].
  • Red flags to escalate to the operator’s flight surgeon before writing any letter: uncontrolled blood pressure, left ventricular hypertrophy or strain on the ECG, angina or ischemia, unexplained fainting, or a drop in blood pressure on standing.
  • Your job: optimize, document, communicate, and route findings to the operator’s flight surgeon.

Read more

Evidence profile
Overall certainty
◆◆◇◇ Low (proposed)
Evidence types
E · Expert / operational / standardsA · Terrestrial analog
Literature through
2026-10-14
Case data
Fictional composite; no real patient data
Credit
Educational only; no CME or other credit
Requirements referenced 2
RequirementTitlePlain-language meaning
[V1 3001]Selection and RecertificationApplies to NASA crew; the rationale notes screening scope may vary by role, including spaceflight participants.
[V1 3002]Pre-Mission Preventive Health CareA useful template for participant preparation: medication review, vaccines, dental care, fitness, health stabilization.

IDs as published in NASA-STD-3001 Vol. 1 Rev C (2023-09-15) and NASA-STD-3001 Vol. 2 Rev F (2026-07-14). NASA-STD-3001 binds NASA programs; it is not a regulation for commercial flights. Paraphrased. Standards quick reference.

References 10
  1. 14 CFR Part 460 — Human Space Flight Requirements. eCFR, current. www.ecfr.gov/current/title-14/chapter-III/subchapter-C/part-… FAA / regulation E
  2. Antuñano MJ, Baisden DL, Davis J, et al. Guidance for Medical Screening of Commercial Aerospace Passengers. FAA Office of Aerospace Medicine; DOT/FAA/AM-06/1. January 2006. www.faa.gov/media/72446 FAA / regulation E
  3. Blue RS, Pattarini JM, Reyes DP, et al. Tolerance of centrifuge-simulated suborbital spaceflight by medical condition. Aviat Space Environ Med. 2014;85(7):721–729. doi:10.3357/ASEM.3956.2014 PMID:25022160 Peer-reviewed A
  4. International Academy of Astronautics Study Group (Antuñano MJ, Gerzer R, chairs). Medical Safety Considerations for Passengers on Short-Duration Commercial Orbital Space Flights (SG26 final report). www.spacemedicineassociates.com/userfiles/file/sg26finalrepo… Organization / other E
  5. Pattarini JM, Blue RS, Castleberry TL, Vanderploeg JM. Preflight screening techniques for centrifuge-simulated suborbital spaceflight. Aviat Space Environ Med. 2014;85(12):1217–1221. doi:10.3357/ASEM.4114.2014 PMID:25479265 Peer-reviewed A
  6. NASA OCHMO. Space Adaptation Sickness (SAS). Medical Technical Brief OCHMO-MTB-004 (2025). www.nasa.gov/wp-content/uploads/2025/09/ochmo-mtb-004-space-… NASA E
  7. NASA OCHMO. Orthostatic Intolerance. Technical Brief OCHMO-TB-019. www.nasa.gov/wp-content/uploads/2023/12/ochmo-tb-019-orthost… NASA E
  8. Bhanu C, Nimmons D, Petersen I, et al. Drug-induced orthostatic hypotension: a systematic review and meta-analysis of randomised controlled trials. PLoS Med. 2021;18(11):e1003821. doi:10.1371/journal.pmed.1003821 PMID:34752479 Peer-reviewed E
  9. Tolerance of beta-blocked hypertensives during orthostatic and altitude stresses (atenolol 100 mg, double-blind crossover, FAA class 3 applicants). DTIC ADA249904, September 1991. archive.org/details/DTIC_ADA249904 FAA / regulation E
  10. Rivasi G, Rafanelli M, Mossello E, Brignole M, Ungar A. Drug-related orthostatic hypotension: beyond anti-hypertensive medications. Drugs Aging. 2020;37(10):725–738. doi:10.1007/s40266-020-00796-5 PMID:32894454 Peer-reviewed E

Machine-checked on 2026-10-14: each URL was fetched, each DOI's title/journal/year matched via Crossref, PubMed IDs matched to DOIs, and claims were checked against the source text (abstract, NASA document or official web page). Human verification against full text is still required before review. NASA documents are U.S. Government works (public domain) and are summarized with attribution; journal articles are summarized, not reproduced.

Article info
Authors
Pending (AI-assisted)
Reviewer
AI-assisted clinical review (AI medical research assistant; no named human clinician)
Last reviewed
2026-10-14
Literature through
2026-10-14
AI-assisted
Yes (disclosed)
COI
Pending
License
CC BY-SA 4.0
Use
Educational only · no CME credit · Disclaimer
Cite this version
Pending first edition

Educational use only · not medical advice · Disclaimer · CC BY-SA 4.0

Search and quick actions

Type to search. Use the up and down arrow keys to move through results, Enter to open, Escape to close.